

## DAFTAR PUSTAKA

- Abbas, A.K. and Lichtman, A.H. 2007. Cellular and Molecular Immunology. 6th ed. WB Saunders Company Saunders, Philadelphia.
- Anderson U, Tracey KJ, (2011) HMGB1 Is A Therapeutic Target For Sterile Inflammation And Infection. *Annu Rev Immunol.* 2011; 29: 139-62.
- Anindita, W. dan Martini, S. 2006. *Faktor Risiko Kejadian Kandidiasis Vaginalis pada Akseptor KB .The Indonesian Journal of Public Health. Vol. 3. No. 1. Juli. 24-28*
- Arya, M., Shergill, I., Williamson, M., Gommersall, L., Arya, N., & Patel, H. (2005) Basic principles of the real time quantitative PCR. *Expert Rev. Mol. Diagn.* 5 (2): 1-11
- Astari I, Ahmad Z. (2019) Pola Pergeseran Penyebab Kandidiasis Vulvovaginalis. *Berkala Ilmu Kesehatan Kulit dan Kelamin – Periodical of Dermatology and Venereology No. 1*
- Baratawidjaja, K.G., Rengganis I. 2010. *Imunologi Dasar ed. 9. Jakarta. BP.FKUI.*
- Batubara I, Mitsunaga T, Ohashi H. (2010), Brazilin From *Caesalpinia Sappan* Wood As An Antiacne Agent. *J Wood Sci.*;56:77-81.
- Budiarto, B. R. (2015). Polymerase Chain Reaction (Pcr) : Perkembangan Dan Perannya Dalam Diagnostik Kesehatan. *Polymerase Chain Reaction (Pcr) : Perkembangan Dan Perannya Dalam Diagnostik Kesehatan, 6(2),*



Couper KN, Blount DG, and Riley EM. Il-10 (2008): The Master Regulator of Immunity to infection. *The Journal of Immunology*; 180(9): 5771-5777

Cui-Lan Tang and Zhi Chen. 2009. Differential gene expression between asymptomatic HBV carriers and normal adults. *Hepatobiliary Pancreas Dis Int.* 8(4); 383-388.

Cushnie, T. P. and Lamb, A. J. 2005. Antimicrobial activity of flavonoids, *International Journal of Antimicrobial Agents*, 26, 343–356.

Damayanti WD (2015). Ekspresi high mobility group box 1 pada ulkus traumatikus tikuswistar dengan terapi ekstrak teripang emas. *J PDGI.* 2015;64(2):95-9. ,Departemen Farmasi Klinis,Fakultas Farmasi universitas Erlangga, hal 44

Direktorat Obat Asli Indonesia. 2008. *Caesalpinia sappan L.* Badan Pengawas Obat dan Makanan Republik Indonesia.

Eling KS, D., Kurniawan, R., & Muhimmah, I. (2014). Karakteristik Primer pada Polymerase Chain Reaction(PCR) untuk Sekuensing DNA: Mini Review. *Seminar Informatika Medis 2014*, 93–102. <http://snimed.fit.uui.ac.id/>

Eraso E, Moragues MD, Villar-Vidal M, Sahand IH, Gonzalez-Gomez N, Ponton J, et al. 2006.Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of *Candidaalbicans* and other medically important *Candida* species. *J Clin Microbiol.* ; 44:3340-5

Gao N and Chen (2016) C. *Candida* Infection: An updated on host Immune responses and Anti Fungal Drugs. *Infectious Disease Translational* line. :2(1):30-40



Grech, V. (2018). WASP (Write a Scientific Paper) using Excel – 8: t-Tests. *Early Human Development*, 121(di), 58–61.

<https://doi.org/10.1016/j.earlhumdev.2018.02.018>

Hakim, L., Ramadhian, M. R., Kedokteran, F. (2015). *Kandidiasis Oral Oral Candidiasis*. 4, 53–57.

Hariana, A. 2006. Tumbuhan Obat dan Khasiatnya. Depok : Niaga Swadaya.

Harris HE, Andersson U, Pisetsky PS. HMGB1: A Multifunctional Alarmin Driving Autoimmune And Inflammatory Disease. *Nat. Rev Rheumatol*. 2012;8195-02.

Hrgvidsdottir HS, Ostberg T, Wahamaa H, et al. The alarmin HMGB1 Acts In Synergy With Endogenous And Exogenous Danger Signal To Promote Inflammation. *J Leukoc Biol*. 2009; 86: 655-62.

Huang, Y., Cao, Y., Li, J., Liu, Y., Zhong, W., Li, X., Chen, C., & Hao, P. (2018). A survey on cellular RNA editing activity in response to *Candida albicans* infections. *BMC Genomics*, 19(Suppl 1). <https://doi.org/10.1186/s12864-017-4374-2>

Kawane K, Tanaka H, Kitahara Y, Shimaoka S, Nagata S. Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. *Proc Natl Acad Sci U S A*. 2010 Nov 9;107(45):19432-7. doi: 10.1073/pnas.1010603107. Epub 2010 Oct 25.

Kelestemur, N. (2012). Department of Parasitology, Faculty of Medicine, Firat University. *The Frequency of Trichomonas vaginalis, Gardnarella vaginalis*

*Candida ssp. Among Infertile Men and Women with Vaginitis,*

Onofrio V, Galle F, Lucariello A, Albano L, Catania MR, Guida M.

*Candida albicans* identification: comparison among nine phenotypic



systems and a multiplex PCR. *J Prev Med Hyg.* 51:121-124.

Made Ni, Slamet (2019) Kandungan senyawa Flavonoid dan Antosianin ekstrak kayu secang (*Caesalpinia Sappan L*) serta aktivitas antibakteri terhadap *Vibrio Cholerae*

Magna M, Pisetsky DS. The Role of HMGB1 in the Pathogenesis Of Inflammatory And Autoimmune Diseases. *Mol Med.* 2014; 20(1): 138-146.

Maharani, K. (2003) Stabilitas Pigmen Brazilin Pada kayu Secang (*Caesalpinia sappan L.*). Skripsi. Bogor: Fakultas Teknologi Pertanian, Institut Pertanian Bogor.

Maharani, K. (2003) Stabilitas pigmen Brazilin Pada kayu Secang (*Caesalpinia sappan L.*). Skripsi. Bogor: Fakultas Teknologi Pertanian, Institut Pertanian Bogor.

Matsumoto S, Kurakado S, Shiokama T, Ando Y, Aoki N, Cho O and Sugita T, 2014. In vitro Synergistic Effects of Anthracycline Antitumor Agents and Fluconazole Against Azole-Resistant *Candida albicans* Clinical Isolates *Journal of Developing Drugs*, Volume 3 , Issue 2

Mayasari D, Wijaya (2018), Potensi Biomarka *High Mobility Group Box 1* (HMGB 1) sebagai Kriteria Diagnosis Asbestosis. 2018. *J Agromedicine*; 5(1): 455 – 457

McClellan S1, Jiang X1, Barrett R1, Hazlett LD. 2015. High-mobility group box 1: a novel target for treatment of *Pseudomonas aeruginosa* keratitis. *J Immunol.* 2015 Feb 15;194(4):1776-87. doi: 10.4049/jimmunol.1401684.

Mechemmed Hatta, Eko E. Surachmanto, Andi Asadul Islam, Syarifuddin Wahid. Expression of mRNA IL-17F and sIL-17F in atopic asthma patients. *Research Notes.*10:202. DOI: 10.1186/s13104-017-2517-9.



Published: 12 June (2017)

Mohan, G., Anand, S.P. & Doss, A. (2011). Efficacy of aqueous and methanol extracts of *Caesalpinia sappan* L. and *Mimosa pudica* L. for their potential antimicrobial activity. *South Asia Journal of Biological Sciences*. 1(2): 48- 57.

Montolalu, C., & Langi, Y. (2018). Pengaruh Pelatihan Dasar Komputer dan Teknologi Informasi bagi Guru-Guru dengan Uji-T Berpasangan (Paired Sample T-Test). *D'CARTESIAN*, 7(1), 44.

<https://doi.org/10.35799/dc.7.1.2018.20113>

Murray RK, et all. *Harper's Biochemistry*. 2005. 25 th ed. Appleton & Lange. 2000; 472-485.

Nabil, Yasmin (2016), Profil Penggunaan Flukonazol pada pasien HIV AIDS

Paul G, Khare V, and Gasche C. Infamed Gut Mucosa: Downstream of Interleukin-10. *European Journal of Clinical Investigation*. 201 ; 2 42(1): 95-109.

PCR untuk Memecahkan Masalah Biologi Terkini.2006. *Penerbit Andi*, Yogyakarta.

Psikologi, F., & Mada, U. G. (2019). *Rancangan Eksperimen-Kuasi Quasi-Experimental Design*. 27(2), 187–203.

<https://doi.org/10.22146/buletinpsikologi.38619>

Ramadhan, G., Hanafi, P., Sulistorini, R. (2017). *Perbandingan Daya Hambat Flukonazol dengan Mikonazol Terhadap Jamur Candida albicans Secara*

*o Prosiding Seminar Nasional Publikasi Hasil-Hasil Penelitian Danabdian Masyarakat "Implementasi Penelitian Dan Pengabdian*



*Masyarakat Untuk Peningkatan Kekayaan Intelektual” Universitas Muhammadiyah Semarang, 30 September 2017, September, 159–162.*

Robert Hotman Sirait, Mochammad Hatta, Muhammad Ramli, Andi Asadul

Islam, Syafrie Kamsul Arief. 2018. Systemic lidocaine inhibits high-mobility group box 1 messenger ribonucleic acid expression and protein in BALB/c mice after closed fracture musculoskeletal injury. *Saudi Journal of Anesthesia*; Vol 12 (3); 395-398; DOI: 10.4103/sja.SJA\_685\_17; Website: [www.saudija.org](http://www.saudija.org); July-September (2018).

Roitt. Pokok Pokok Ilmu Kekebalan. 1997. Jakarta. Gramedia

Sari R., Suhartati. Secang (*Caesalpinia sappan* L.) ,2016 : Tumbuhan Herbal Kaya Antioksidan. *Info Teknis EBONI* Vol. 13 No. 1, Juni : 57 - 67

Saydam, S.G. 2012. Waspada Penyakit Reproduksi Anda. Bandung: Pustaka Reka Cipta.

Scaffidi P, Mistell T, Bianchi ME. , 2002 Release Of Chromatin Protein HMGB1 By Necrotic Cells Triggers Inflammation. *Nature*. 418: 191-5.

Scheller J, Chalaris A, Schmidt-Arras D, and RoseJohn S. The Pro- and Anti-Inflammatory Properties of the Cytokine Interleukin-6. *Biochimica et Biophysica Acta*. 2011; : 878-888

Seleem D, Chen E, Benso B Pardi V, and Murata RM, 2016. In vitro Evaluation of fungal activity of Monolaurin against candida albicans biofilms, *PeerJ*.4 :e2148

Sobel JD. Vulvovaginal Candidiasis. In: Holmes KK, editor. *Sexually Transmitted Diseases*. 4th ed. New York: Mc Graw Hill; 2008.p. 823 – 35.

Selvam, G.G., Karthik, S., Mathivanan, K., Baskaran, R., An, M., Gopi, M. & Govindasamy, C. (2012). In vitro antimicrobial



activity of *Caesalpinia sappan* L. *Asian Pacific Journal of Tropical Biomedicine*. 2(1): S136-S139.

Suri, B., Kageorge, L., Grigoriev, R. O., & Schatz, M. F. (2020). Capturing Turbulent Dynamics and Statistics in Experiments with Unstable Periodic Orbits. *Physical Review Letters*, 125(6), 64501.  
<https://doi.org/10.1103/PhysRevLett.125.064501>

Suriani, Enlita. 2015 Uji Potensi Ekstrak Kayu secang (*Caesalpinia Sappan* L.) dalam menghambat pertumbuhan jamur *Candida albicans*

Tizard. 2004. *Veterinary Immunology. An Introduction*. 6th ed. WB Saunders Company. Philadelphia.

Tomomi Yajima, Atsuhito Yagihashi, Daisuke Furuya, Hidekazu Kameshim. **1998**. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. *Clinical Chemistry* 44:12. 2441–2445

Yang H, Antonie DJ, Andersson U, et al. The many faces of HMGB1 (2013): Molecular Structure-Functional Activity In Inflammation, Apoptosis, And Chemotaxis. *J Leukoc Biol.*; 93: 865-73.

Yuwono T. *Teori dan Aplikasi Polymerase Chain Reaction, Panduan Eksperimen*



# LAMPIRAN





## DAFTAR RIWAYAT HIDUP



### DATA PRIBADI :

Nama Lengkap : dr. Sri Wahyu, M.Kes,  
 Tempat/Tanggal Lahir : Ujung Pandang, 7 Maret 1982  
 Agama : Islam  
 Nama Suami : Andi Fara Kessi, S.STP, M.M  
 Pangkat/ Jabatan Fungsi : Asisten Ahli, Golongan III/B  
 Pekerjaan : Dosen Fakultas Kedokteran Universitas Muslim Indonesia

### Riwayat Pendidikan :

Tahun 1994 : SD Mongisidi III Makassar  
 Tahun 1997 : SMP Negeri 2 Makassar  
 Tahun 2000 : SMU Negeri 2 Makassar  
 Tahun 2005 : S1 Kedokteran Universitas Muslim Indonesia  
 Tahun 2008 : Profesi Dokter Universitas Muslim Indonesia  
 Tahun 2012 : Magister Biomedik Fakultas Kedokteran Universitas Hasanuddin

### Riwayat Pekerjaan :

1. Dokter Umum di Rumah Sakit Khusus Daerah (RSKD) Dadi Makassar 2008-2011
2. Dokter di Klinik Bank Indonesia (2010-2012)
3. Dokter di Klinik BOSOWA (2010-2014)
4. Sekretaris Bagian Fisiologi Fakultas Kedokteran Universitas Muslim Indonesia (2009-Sekarang)



### Penyertaan/Kursus/Seminar :

PEKERTI, 2012 di Universitas Muslim Indonesia  
 Supervisi KKN, 2017 di Universitas Muslim Indonesia

3. Pelatihan Applied Approach, 2018 di Makassar
4. Pelatihan Animasi Sebagai Bahan Pembelajaran dalam Pendidikan Kedokteran,2012 di FK UGM, Jogyakarta
5. Pelatihan Aplikasi teknik Biologi Biomolekuler dan Imunologi dalam Penelitian Bidang Kesehatan,2016 di FK UNHAS, Makassar
6. Scientific Writing Workshop,2018 di FK Pajajaran, Bandung
7. Pelatihan Cara Uji Klinik yang Baik (CUKB) / Good Clinical Practice (GCP),2020 DI FK UNHAS, Makassar



## A. Cara pembuatan Ekstrak Kayu Secang (*C. Sappan*)



Sediaan Kayu secang (*C. Sappan*)




Kayu secang dipotong kecil dan tipis dulu



Penimbangan Kayu Secang



Kayu secang ditambah pelarut etanol baru diekstraksi secara reflux



Ekstrak cair setelah penyaringan



Rotary evaporator utk pekatkan ekstrak cair, pisahkan pelarut



Water bath menguapkan sisa pelarut dr ekstrak pekat




Lempeng pemanas utk keringkan ekstrak






Bahan untuk 3 Kelompok Sampel Kuratif



Bahan untuk Preventif



## B. Pemberian Infeksi (Candida Albicans)



Pemberian Obat anti Kandida (Flukonazol 19.5 mg/20 KgBB Mencit)



Pemberian Kayu Secang (C. Sappan)

0



Pengambilan Sampling Kultur dengan Cotton Bath



Pemberian Ekstrak Kayu Secang



No	Kelompok	Sampel 1		Sampel 2		Sampel 3		Sampel 4		Ket.
		L6	Serum	L6	Serum	L6	Serum	L6	Serum	
1	I. Kontrol	LA01	SA01	LB01	SB01	LC01	SC01	LD01	SD01	Preventif (-) )/Placebo dan Kuratif (-) / Placebo
2		LA02	SA02	LB02	SB02	LC02	SC02	LD02	SD02	
3		LA03	SA03	LB03	SB03	LC03	SC03	LD03	SD03	
4		LA04	SA04	LB04	SB04	LC04	SC04	LD04	SD04	
5		LA05	SA05	LB05	SB05	LC05	SC05	LD05	SD05	
6	II. Obat (Fluconazole)	LA06	SA06	LB06	SB06	LC06	SC06	LD06	SD06	Preventif eks. Kayu secang dan Kuratif obat (Fluconazole)
7		LA07	SA07	LB07	SB07	LC07	SC07	LD07	SD07	
8		LA08	SA08	LB08	SB08	LC08	SC08	LD08	SD08	
9		LA09	SA09	LB09	SB09	LC09	SC09	LD09	SD09	
10		LA10	SA10	LB10	SB10	LC10	SC10	LD10	SD10	
11	III. Eks. Kayu Secang	LA11	SA11	LB11	SB11	LC11	SC11	LD11	SD11	Preventif eks. Kayu secang dan Kuratif eks. Kayu secang
12		LA12	SA12	LB12	SB12	LC12	SC12	LD12	SD12	
13		LA13	SA13	LB13	SB13	LC13	SC13	LD13	SD13	
14		LA14	SA14	LB14	SB14	LC14	SC14	LD14	SD14	
15		LA15	SA15	LB15	SB15	LC15	SC15	LD15	SD15	

Ket  
sampel:

- 1: Sebelum Perlakuan
- 2: Setelah pemberian ekstrak kayu secang selama 10 hari (preventif)
- 3: Setelah pemberian ekstrak kayu secang selama 10 hari (preventif) dan infeksi Candida 1 hari
- 4: Setelah selesai pengobatan selama 7 hari











### C. Daftar Hasil Kultur

No	Kelompok	Setelah Infeksi	Setelah Pengobatan	Ket
1	I.Kontrol	61	TBUD	Preventif : Negatif (Placebo)
2		54	TBUD	
3		57	TBUD	
4		60	TBUD	
5		54	TBUD	
6		56	TBUD	Cadangan
7	II.Obat (Fluconazole)	47	0	Preventif : Eks. Kayu Secang
8		42	0	
9		48	3	
10		48	0	
11		45	1	
12		47	1	Cadangan
13	III.Ekstrak Kayu Secangl	49	30	Preventif : Eks. Kayu Secang
14		43	27	
15		44	24	
16		45	29	
17		42	30	
18		50	25	Cadangan



**D. Gambaran Hasil Kultur**

KLP	Setelah Infeksi	Setelah Pengobatan
I		
II		
III		



**E. HASIL PEMERIKSAAN MOUSE HMGB1 ELISA KIT CAT. NO. LS-F11642**

No	No Sampel	Konsentrasi (ng/ml)
1	LC01	92.326
2	LC02	99.907
3	LC03	106.946
4	LC04	87.995
5	LC05	76.624
6	LC06	71.209
7	LC07	95.575
8	LC08	59.297
9	LC09	83.122
10	LC10	54.966
11	LC11	73.917
12	LC12	79.331
13	LC13	69.585
14	LC14	90.160
15	LC15	93.951
16	LD01	125.897
17	LD02	149.721
18	LD03	135.101
19	LD04	146.472
20	LD05	139.433
21	LD06	30.059
22	LD07	25.727
23	LD08	12.191
24	LD09	34.390
25	LD10	40.346
26	LD11	67.419
27	LD12	73.375
28	LD13	45.761
29	LD14	52.800
30	LD15	65.253



**F. HASIL PEMERIKSAAN MOUSE INTERLEUKIN-6 ELISA KIT CAT. NO. LS-F24855**

No	No Sampel	Konsentrasi (pg/ml)
1	LC01	4,309.404
2	LC02	3,595.750
3	LC03	4,012.048
4	LC04	4,844.644
5	LC05	5,082.529
6	LC06	3,516.455
7	LC07	3,912.929
8	LC08	3,318.217
9	LC09	2,822.624
10	LC10	4,210.285
11	LC11	3,100.157
12	LC12	2,981.214
13	LC13	4,111.166
14	LC14	3,793.987
15	LC15	3,417.336
16	LD01	5,578.122
17	LD02	6,232.304
18	LD03	5,399.708
19	LD04	6,093.538
20	LD05	5,260.942
21	LD06	2,426.150
22	LD07	1,890.910
23	LD08	1,236.727
24	LD09	1,692.672
25	LD10	2,267.560
26	LD11	2,782.977
27	LD12	2,664.035
28	LD13	2,505.445
29	LD14	2,901.919
30	LD15	3,159.628



**G. HASIL PEMERIKSAAN MOUSE INTERLEUKIN-10 ELISA KIT CAT. NO. LS-F11734**

No	No Sampel	Konsentrasi (pg/ml)
1	LC01	3,400.755
2	LC02	4,018.602
3	LC03	3,135.963
4	LC04	6,181.068
5	LC05	5,474.957
6	LC06	885.234
7	LC07	2,518.116
8	LC08	1,238.290
9	LC09	3,797.943
10	LC10	1,414.817
11	LC11	2,032.665
12	LC12	2,385.720
13	LC13	3,003.568
14	LC14	532.178
15	LC15	1,105.894
16	LD01	2,871.172
17	LD02	3,621.415
18	LD03	1,767.873
19	LD04	2,209.192
20	LD05	3,930.338
21	LD06	3,268.359
22	LD07	3,533.151
23	LD08	1,635.477
24	LD09	3,886.207
25	LD10	1,944.401
26	LD11	2,562.248
27	LD12	3,665.547
28	LD13	3,753.811
29	LD14	2,297.456
30	LD15	3,091.831



**H. HASIL PEMERIKSAAN MOUSE HMGB1 ELISA KIT CAT. NO. LS-F11642**

No	No Sampel	Konsentrasi (ng/ml)
1	LC01	92.326
2	LC02	99.907
3	LC03	106.946
4	LC04	87.995
5	LC05	76.624
6	LC06	71.209
7	LC07	95.575
8	LC08	59.297
9	LC09	83.122
10	LC10	54.966
11	LC11	73.917
12	LC12	79.331
13	LC13	69.585
14	LC14	90.160
15	LC15	93.951
16	LD01	125.897
17	LD02	149.721
18	LD03	135.101
19	LD04	146.472
20	LD05	139.433
21	LD06	30.059
22	LD07	25.727
23	LD08	12.191
24	LD09	34.390
25	LD10	40.346
26	LD11	67.419
27	LD12	73.375
28	LD13	45.761
29	LD14	52.800
30	LD15	65.253



**I. PEMERIKSAAN MOUSE INTERLEUKIN-6 ELISA KIT CAT. NO. LS-F24855**

No	No Sampel	Konsentrasi (pg/ml)
1	LC01	4,309.404
2	LC02	3,595.750
3	LC03	4,012.048
4	LC04	4,844.644
5	LC05	5,082.529
6	LC06	3,516.455
7	LC07	3,912.929
8	LC08	3,318.217
9	LC09	2,822.624
10	LC10	4,210.285
11	LC11	3,100.157
12	LC12	2,981.214
13	LC13	4,111.166
14	LC14	3,793.987
15	LC15	3,417.336
16	LD01	5,578.122
17	LD02	6,232.304
18	LD03	5,399.708
19	LD04	6,093.538
20	LD05	5,260.942
21	LD06	2,426.150
22	LD07	1,890.910
23	LD08	1,236.727
24	LD09	1,692.672
25	LD10	2,267.560
26	LD11	2,782.977
27	LD12	2,664.035
28	LD13	2,505.445
29	LD14	2,901.919
30	LD15	3,159.628



**J. HASIL PEMERIKSAAN MOUSE INTERLEUKIN-10 ELISA KIT CAT. NO. LS-F11734**

No	No Sampel	Konsentrasi (pg/ml)
1	LC01	3,400.755
2	LC02	4,018.602
3	LC03	3,135.963
4	LC04	6,181.068
5	LC05	5,474.957
6	LC06	885.234
7	LC07	2,518.116
8	LC08	1,238.290
9	LC09	3,797.943
10	LC10	1,414.817
11	LC11	2,032.665
12	LC12	2,385.720
13	LC13	3,003.568
14	LC14	532.178
15	LC15	1,105.894
16	LD01	2,871.172
17	LD02	3,621.415
18	LD03	1,767.873
19	LD04	2,209.192
20	LD05	3,930.338
21	LD06	3,268.359
22	LD07	3,533.151
23	LD08	1,635.477
24	LD09	3,886.207
25	LD10	1,944.401
26	LD11	2,562.248
27	LD12	3,665.547
28	LD13	3,753.811
29	LD14	2,297.456
30	LD15	3,091.831



Optimization Software:  
[www.balesio.com](http://www.balesio.com)



## K. Uji Statistik

## Explore

Descriptives<sup>a</sup>

	Kelompok		Statistic	Std. Error	
KoloniSebelum	Kelompok kontrol	Mean	57,2000	1,46287	
		95% Confidence Interval for Mean	Lower Bound	53,1384	
			Upper Bound	61,2616	
		5% Trimmed Mean	57,1667		
		Median	57,0000		
		Variance	10,700		
		Std. Deviation	3,27109		
		Minimum	54,00		
		Maximum	61,00		
		Range	7,00		
		Interquartile Range	6,50		
		Skewness	,134	,913	
		Kurtosis	-2,763	2,000	
		Fluconazol		Mean	46,0000
95% Confidence Interval for Mean	Lower Bound			42,8344	
	Upper Bound			49,1656	



	5% Trimmed Mean	46,1111	
	Median	47,0000	
	Variance	6,500	
	Std. Deviation	2,54951	
	Minimum	42,00	
	Maximum	48,00	
	Range	6,00	
	Interquartile Range	4,50	
	Skewness	-1,207	,913
	Kurtosis	,580	2,000
Secang	Mean	44,6000	1,20830
	95% Confidence Interval for Mean	Lower Bound	41,2452
		Upper Bound	47,9548
	5% Trimmed Mean	44,5000	
	Median	44,0000	
	Variance	7,300	
	Std. Deviation	2,70185	
	Minimum	42,00	
	Maximum	49,00	
	Range	7,00	
	Interquartile Range	4,50	



		Skewness	1,339	,913
		Kurtosis	2,021	2,000
KoloniSesudah	Fluconazol	Mean	,8000	,58310
		95% Confidence Interval for Mean		
		Lower Bound	-,8189	
		Upper Bound	2,4189	
		5% Trimmed Mean	,7222	
		Median	,0000	
		Variance	1,700	
		Std. Deviation	1,30384	
		Minimum	,00	
		Maximum	3,00	
		Range	3,00	
		Interquartile Range	2,00	
		Skewness	1,714	,913
		Kurtosis	2,664	2,000
	Secang	Mean	28,0000	1,14018
		95% Confidence Interval for Mean		
		Lower Bound	24,8344	
		Upper Bound	31,1656	
		5% Trimmed Mean	28,1111	
		Median	29,0000	
		Variance	6,500	



		Std. Deviation	2,54951	
		Minimum	24,00	
		Maximum	30,00	
		Range	6,00	
		Interquartile Range	4,50	
		Skewness	-1,207	,913
		Kurtosis	,580	2,000
IL6_sebelum	Kelompok kontrol	Mean	4368,8750	270,57741
		95% Confidence Interval for Mean	Lower Bound	3617,6317
			Upper Bound	5120,1183
		5% Trimmed Mean	4372,1789	
		Median	4309,4040	
		Variance	366060,687	
		Std. Deviation	605,02949	
		Minimum	3595,75	
		Maximum	5082,53	
		Range	1486,78	
		Interquartile Range	1159,69	
		Skewness	-,069	,913
		Kurtosis	-1,618	2,000
	Fluconazol	Mean	3556,1020	239,94083
		95% Confidence Interval for Mean	Lower Bound	2889,9195



	Upper Bound	4222,2845	
	5% Trimmed Mean	3560,5073	
	Median	3516,4550	
	Variance	287858,010	
	Std. Deviation	536,52401	
	Minimum	2822,62	
	Maximum	4210,29	
	Range	1387,66	
	Interquartile Range	991,19	
	Skewness	-,223	,913
	Kurtosis	-,578	2,000
Secang	Mean	3480,7720	211,41787
	95% Confidence Interval for Mean		
	Lower Bound	2893,7819	
	Upper Bound	4067,7621	
	5% Trimmed Mean	3473,5033	
	Median	3417,3360	
	Variance	223487,583	
	Std. Deviation	472,74473	
	Minimum	2981,21	
	Maximum	4111,17	
	Range	1129,95	
	Interquartile Range	911,89	



		Skewness	,399	,913	
		Kurtosis	-1,723	2,000	
IL6_sesudah	Kelompok kontrol	Mean	5712,9228	191,72717	
		95% Confidence Interval for Mean	Lower Bound	5180,6028	
			Upper Bound	6245,2428	
		5% Trimmed Mean		5709,1783	
		Median		5578,1220	
		Variance		183796,543	
		Std. Deviation		428,71499	
		Minimum		5260,94	
		Maximum		6232,30	
		Range		971,36	
		Interquartile Range		832,60	
		Skewness		,369	,913
		Kurtosis		-2,618	2,000
		Fluconazol	Mean	1902,8038	211,52937
		95% Confidence Interval for Mean	Lower Bound	1315,5041	
			Upper Bound	2490,1035	
		5% Trimmed Mean		1910,7333	
		Median		1890,9100	
		Variance		223723,367	



	Std. Deviation	472,99405	
	Minimum	1236,73	
	Maximum	2426,15	
	Range	1189,42	
	Interquartile Range	882,16	
	Skewness	-,445	,913
	Kurtosis	-,720	2,000
Secang	Mean	2802,8008	110,72928
	95% Confidence Interval for Mean	Lower Bound	2495,3670
		Upper Bound	3110,2346
	5% Trimmed Mean	2799,4968	
	Median	2782,9770	
	Variance	61304,868	
	Std. Deviation	247,59820	
	Minimum	2505,45	
	Maximum	3159,63	
	Range	654,18	
	Interquartile Range	446,03	
	Skewness	,479	,913
	Kurtosis	,148	2,000
Kelompok kontrol	Mean	4442,2690	594,16105
	95% Confidence Interval for Mean	Lower Bound	2792,6135



	Upper Bound	6091,9245	
	5% Trimmed Mean	4418,2416	
	Median	4018,6020	
	Variance	1765136,74 3	
	Std. Deviation	1328,58449	
	Minimum	3135,96	
	Maximum	6181,07	
	Range	3045,11	
	Interquartile Range	2559,65	
	Skewness	,519	,913
	Kurtosis	-2,223	2,000
Fluconazol	Mean	1970,8800	532,07837
	95% Confidence Interval for Mean		
	Lower Bound	493,5936	
	Upper Bound	3448,1664	
	5% Trimmed Mean	1929,6902	
	Median	1414,8170	
	Variance	1415536,96 3	
	Std. Deviation	1189,76341	
	Minimum	885,23	
	Maximum	3797,94	
	Range	2912,71	





		Interquartile Range	2096,27	
		Skewness	1,093	,913
		Kurtosis	,113	2,000
Secang		Mean	1812,0050	443,52069
		95% Confidence Interval for Mean		
		Lower Bound	580,5942	
		Upper Bound	3043,4158	
		5% Trimmed Mean	1816,9086	
		Median	2032,6650	
		Variance	983553,004	
		Std. Deviation	991,74241	
		Minimum	532,18	
		Maximum	3003,57	
		Range	2471,39	
		Interquartile Range	1875,61	
		Skewness	-,238	,913
		Kurtosis	-1,464	2,000
IL10_sesudah	Kelompok kontrol	Mean	2879,9980	408,64373
		95% Confidence Interval for Mean		
		Lower Bound	1745,4211	
		Upper Bound	4014,5749	
		5% Trimmed Mean	2883,4305	
		Median	2871,1720	



	Variance		834948,472	
	Std. Deviation		913,75515	
	Minimum		1767,87	
	Maximum		3930,34	
	Range		2162,47	
	Interquartile Range		1787,34	
	Skewness		-,061	,913
	Kurtosis		-2,170	2,000
Fluconazol	Mean		2853,5190	447,80343
	95% Confidence Interval for Mean	Lower Bound	1610,2174	
		Upper Bound	4096,8206	
	5% Trimmed Mean		2863,8164	
	Median		3268,3590	
	Variance		1002639,56 0	
	Std. Deviation		1001,31891	
	Minimum		1635,48	
	Maximum		3886,21	
	Range		2250,73	
	Interquartile Range		1919,74	
	Skewness		-,445	,913
	Kurtosis		-2,697	2,000
Secang	Mean		3074,1786	289,59449



		95% Confidence Interval for Mean	Lower Bound	2270,1354	
			Upper Bound	3878,2218	
		5% Trimmed Mean		3079,5725	
		Median		3091,8310	
		Variance		419324,832	
		Std. Deviation		647,55296	
		Minimum		2297,46	
		Maximum		3753,81	
		Range		1456,36	
		Interquartile Range		1279,83	
		Skewness		-,126	,913
		Kurtosis		-2,538	2,000
EkspresiGenSe	Kelompok kontrol	Mean		11,7970	,21852
		95% Confidence Interval for Mean	Lower Bound	11,1903	
			Upper Bound	12,4037	
		5% Trimmed Mean		11,8018	
		Median		11,8230	
		Variance		,239	
		Std. Deviation		,48863	
		Minimum		11,17	
		Maximum		12,34	



	Range		1,17	
	Interquartile Range		,95	
	Skewness		-,228	,913
	Kurtosis		-1,949	2,000
Fluconazol	Mean		11,2242	,27832
	95% Confidence Interval for Mean	Lower Bound	10,4514	
		Upper Bound	11,9970	
	5% Trimmed Mean		11,2362	
	Median		11,3300	
	Variance		,387	
	Std. Deviation		,62235	
	Minimum		10,39	
	Maximum		11,85	
	Range		1,46	
	Interquartile Range		1,20	
	Skewness		-,467	,913
	Kurtosis		-1,786	2,000
Secang	Mean		11,2572	,25849
	95% Confidence Interval for Mean	Lower Bound	10,5395	
		Upper Bound	11,9749	
	5% Trimmed Mean		11,2551	



		Median	11,2220	
		Variance	,334	
		Std. Deviation	,57799	
		Minimum	10,67	
		Maximum	11,89	
		Range	1,22	
		Interquartile Range	1,15	
		Skewness	,087	,913
		Kurtosis	-2,923	2,000
EkspresiGensesudah	Kelompok kontrol	Mean	13,6516	,16185
		95% Confidence Interval for Mean	Lower Bound	13,2022
			Upper Bound	14,1010
		5% Trimmed Mean	13,6413	
		Median	13,6280	
		Variance	,131	
		Std. Deviation	,36191	
		Minimum	13,27	
		Maximum	14,22	
		Range	,95	
		Interquartile Range	,62	
		Skewness	1,015	,913
		Kurtosis	1,303	2,000



Fluconazol	Mean		9,0344	,33590
	95% Confidence Interval for Mean	Lower Bound	8,1018	
		Upper Bound	9,9670	
	5% Trimmed Mean		9,0374	
	Median		9,3230	
	Variance		,564	
	Std. Deviation		,75110	
	Minimum		8,16	
	Maximum		9,86	
	Range		1,70	
	Interquartile Range		1,44	
	Skewness		-,336	,913
	Kurtosis		-2,641	2,000
Secang	Mean		10,2262	,21282
	95% Confidence Interval for Mean	Lower Bound	9,6353	
		Upper Bound	10,8171	
	5% Trimmed Mean		10,2217	
	Median		10,2980	
	Variance		,226	
	Std. Deviation		,47587	
	Minimum		9,70	



		Maximum	10,83	
		Range	1,13	
		Interquartile Range	,92	
		Skewness	,081	,913
		Kurtosis	-1,917	2,000
Solubleprotein_sebelum	Kelompok kontrol	Mean	92,7596	5,17487
		95% Confidence Interval for Mean	Lower Bound	78,3918
			Upper Bound	107,1274
		5% Trimmed Mean	92,8679	
		Median	92,3260	
		Variance	133,897	
		Std. Deviation	11,57137	
		Minimum	76,62	
		Maximum	106,95	
		Range	30,32	
		Interquartile Range	21,12	
		Skewness	-,293	,913
		Kurtosis	-,232	2,000
	Fluconazol	Mean	72,8338	7,51050
		95% Confidence Interval for Mean	Lower Bound	51,9813
			Upper Bound	93,6863



	5% Trimmed Mean	72,5631	
	Median	71,2090	
	Variance	282,038	
	Std. Deviation	16,79399	
	Minimum	54,97	
	Maximum	95,58	
	Range	40,61	
	Interquartile Range	32,22	
	Skewness	,410	,913
	Kurtosis	-1,492	2,000
Secang	Mean	81,3888	4,65905
	95% Confidence Interval for Mean	Lower Bound	68,4532
		Upper Bound	94,3244
	5% Trimmed Mean	81,3467	
	Median	79,3310	
	Variance	108,534	
	Std. Deviation	10,41795	
	Minimum	69,59	
	Maximum	93,95	
	Range	24,37	
	Interquartile Range	20,30	
	Skewness	,216	,913





		Kurtosis	-2,337	2,000	
solubleprotein_sesudah	Kelompok kontrol	Mean	139,3248	4,22683	
		95% Confidence Interval for Mean	Lower Bound	127,5892	
			Upper Bound	151,0604	
		5% Trimmed Mean	139,4932		
		Median	139,4330		
		Variance	89,330		
		Std. Deviation	9,45147		
		Minimum	125,90		
		Maximum	149,72		
		Range	23,82		
		Interquartile Range	17,60		
		Skewness	-,497	,913	
		Kurtosis	-,619	2,000	
		Fluconazol		Mean	28,5426
95% Confidence Interval for Mean	Lower Bound			15,3565	
	Upper Bound			41,7287	
5% Trimmed Mean	28,7953				
Median	30,0590				
Variance	112,779				



	Std. Deviation		10,61972	
	Minimum		12,19	
	Maximum		40,35	
	Range		28,15	
	Interquartile Range		18,41	
	Skewness		-,886	,913
	Kurtosis		1,055	2,000
Secang	Mean		60,9216	5,05899
	95% Confidence Interval for Mean	Lower Bound	46,8756	
		Upper Bound	74,9676	
	5% Trimmed Mean		61,0720	
	Median		65,2530	
	Variance		127,967	
	Std. Deviation		11,31226	
	Minimum		45,76	
	Maximum		73,38	
	Range		27,61	
	Interquartile Range		21,12	
	Skewness		-,499	,913
	Kurtosis		-1,636	2,000



constant when Kelompok = Kelompok kontrol. It has been omitted.

Percentiles<sup>a</sup>

			Percentiles						
			5	10	25	50	75	90	95
Weighted Average(Definiton 1)	KoloniSebelum	Kelompok kontrol	54,000 0	54,000 0	54,000 0	57,000 0	60,500 0	.	.
		Fluconazol	42,000 0	42,000 0	43,500 0	47,000 0	48,000 0	.	.
		Secang	42,000 0	42,000 0	42,500 0	44,000 0	47,000 0	.	.
	KoloniSesudah	Fluconazol	,0000	,0000	,0000	,0000	2,0000	.	.
		Secang	24,000 0	24,000 0	25,500 0	29,000 0	30,000 0	.	.
	IL6_sebelum	Kelompok kontrol	3595,7 500	3595,7 500	3803,8 990	4309,4 040	4963,5 865	.	.
		Fluconazol	2822,6 240	2822,6 240	3070,4 205	3516,4 550	4061,6 070	.	.
		Secang	2981,2 140	2981,2 140	3040,6 855	3417,3 360	3952,5 765	.	.
	IL6_sesudah	Kelompok kontrol	5260,9 420	5260,9 420	5330,3 250	5578,1 220	6162,9 210	.	.
		Fluconazol	1236,7 270	1236,7 270	1464,6 995	1890,9 100	2346,8 550	.	.
		Secang	2505,4 450	2505,4 450	2584,7 400	2782,9 770	3030,7 735	.	.



IL10_sebelum	Kelompok kontrol	3135,9 630	3135,9 630	3268,3 590	4018,6 020	5828,0 125		
	Fluconazol	885,23 40	885,23 40	1061,7 620	1414,8 170	3158,0 295		
	Secang	532,17 80	532,17 80	819,03 60	2032,6 650	2694,6 440		
IL10_sesudah	Kelompok kontrol	1767,8 730	1767,8 730	1988,5 325	2871,1 720	3775,8 765		
	Fluconazol	1635,4 770	1635,4 770	1789,9 390	3268,3 590	3709,6 790		
	Secang	2297,4 560	2297,4 560	2429,8 520	3091,8 310	3709,6 790		
EkspresiGenSe	Kelompok kontrol	11,171 0	11,171 0	11,315 5	11,823 0	12,265 5		
	Fluconazol	10,388 0	10,388 0	10,597 0	11,330 0	11,798 5		
	Secang	10,665 0	10,665 0	10,689 5	11,222 0	11,842 5		
EkspresiGenses udah	Kelompok kontrol	13,269 0	13,269 0	13,347 5	13,628 0	13,967 5		
	Fluconazol	8,1550	8,1550	8,2420	9,3230	9,6825		
	Secang	9,7020	9,7020	9,7500	10,298 0	10,666 5		
Solubleprotein_s ebelum	Kelompok kontrol	76,624 0	76,624 0	82,309 5	92,326 0	103,42 65		
	Fluconazol	54,966 0	54,966 0	57,131 5	71,209 0	89,348 5		
	Secang	69,585 0	69,585 0	71,751 0	79,331 0	92,055 5		



solubleprotein_s esudah	Kelompok kontrol	125,89 70	125,89 70	130,49 90	139,43 30	148,09 65		
	Fluconazol	12,191 0	12,191 0	18,959 0	30,059 0	37,368 0		
	Secang	45,761 0	45,761 0	49,280 5	65,253 0	70,397 0		

a. KoloniSesudah is constant when Kelompok = Kelompok kontrol. It has been omitted.

## Wilcoxon Signed Ranks Test

### Test Statistics<sup>a</sup>

	KoloniSesudah - KoloniSebelum	IL6_sesudah - IL6_sebelum	IL10_sesudah - IL10_sebelum	EkspresiGenses udah - EkspresiGenSe
Z	-,739 <sup>b</sup>	-,966 <sup>b</sup>	-,966 <sup>c</sup>	-,738 <sup>b</sup>
Asymp. Sig. (2-tailed)	,460	,334	,334	,460

### Test Statistics<sup>a</sup>

	solubleprotein_sesudah - Solubleprotein_sebelum
Z	-,511 <sup>b</sup>
Asymp. Sig. (2-tailed)	,609

## Explore



Optimization Software:  
[www.balesio.com](http://www.balesio.com)

### Descriptives

ompok	Statistic	Std. Error

delta_koloni	Kelompok kontrol	Mean		42,8000	1,46287
		95% Confidence Interval for Mean	Lower Bound	38,7384	
			Upper Bound	46,8616	
		5% Trimmed Mean		42,8333	
		Median		43,0000	
		Variance		10,700	
		Std. Deviation		3,27109	
		Minimum		39,00	
		Maximum		46,00	
		Range		7,00	
		Interquartile Range		6,50	
		Skewness		-,134	,913
		Kurtosis		-2,763	2,000
		Fluconazol		Mean	
95% Confidence Interval for Mean	Lower Bound			-48,1644	
	Upper Bound			-42,2356	
5% Trimmed Mean				-45,2222	
Median				-45,0000	
Variance				5,700	
Std. Deviation				2,38747	
Minimum				-48,00	
Maximum				-42,00	
Range				6,00	



		Interquartile Range	4,50	
		Skewness	,206	,913
		Kurtosis	-1,117	2,000
Secang		Mean	-16,6000	1,40000
		95% Confidence Interval for Mean	Lower Bound -20,4870 Upper Bound -12,7130	
		5% Trimmed Mean	-16,6667	
		Median	-16,0000	
		Variance	9,800	
		Std. Deviation	3,13050	
		Minimum	-20,00	
		Maximum	-12,00	
		Range	8,00	
		Interquartile Range	5,50	
		Skewness	,606	,913
		Kurtosis	,002	2,000
delta_IL6	Kelompok kontrol	Mean	1344,0478	390,25041
		95% Confidence Interval for Mean	Lower Bound 260,5390 Upper Bound 2427,5566	
		5% Trimmed Mean	1336,9994	
		Median	1268,7180	
		Variance	761476,903	
		Std. Deviation	872,62644	



	Minimum		178,41	
	Maximum		2636,55	
	Range		2458,14	
	Interquartile Range		1298,45	
	Skewness		,360	,913
	Kurtosis		1,996	2,000
Fluconazol	Mean		-1653,2982	222,92641
	95% Confidence Interval for Mean	Lower Bound	-2272,2411	
		Upper Bound	-1034,3553	
	5% Trimmed Mean		-1660,7872	
	Median		-1942,7250	
	Variance		248480,927	
	Std. Deviation		498,47861	
	Minimum		-2081,49	
	Maximum		-1090,30	
	Range		991,19	
	Interquartile Range		941,63	
	Skewness		,568	,913
	Kurtosis		-3,250	2,000
Secang	Mean		-677,9712	259,18329
	95% Confidence Interval for Mean	Lower Bound	-1397,5794	
		Upper Bound	41,6370	
	5% Trimmed Mean		-649,7775	
	Median		-317,1800	





		Variance		335879,898	
		Std. Deviation		579,55146	
		Minimum		-1605,72	
		Maximum		-257,71	
		Range		1348,01	
		Interquartile Range		961,45	
		Skewness		-1,370	,913
		Kurtosis		,953	2,000
delta_IL10	Kelompok kontrol	Mean		-1562,2710	642,96498
		95% Confidence Interval for Mean	Lower Bound	-3347,4280	
			Upper Bound	222,8860	
		5% Trimmed Mean		-1493,1309	
		Median		-1368,0900	
		Variance		2067019,836	
		Std. Deviation		1437,71341	
		Minimum		-3971,88	
		Maximum		-397,19	
		Range		3574,69	
		Interquartile Range		2294,86	
		Skewness		-1,584	,913
		Kurtosis		2,735	2,000
	conazol	Mean		882,6390	403,75302
		95% Confidence Interval for Mean	Lower Bound	-238,3591	
			Upper Bound	2003,6371	



	5% Trimmed Mean		843,4106	
	Median		529,5840	
	Variance		815082,514	
	Std. Deviation		902,81920	
	Minimum		88,26	
	Maximum		2383,13	
	Range		2294,86	
	Interquartile Range		1456,35	
	Skewness		1,541	,913
	Kurtosis		2,421	2,000
Secang	Mean		1262,1736	280,71525
	95% Confidence Interval for Mean	Lower Bound	482,7831	
		Upper Bound	2041,5641	
	5% Trimmed Mean		1262,6640	
	Median		1279,8270	
	Variance		394005,266	
	Std. Deviation		627,69839	
	Minimum		529,58	
	Maximum		1985,94	
	Range		1456,35	
	Interquartile Range		1235,69	
	Skewness		-,035	,913
	Kurtosis		-2,402	2,000
ompok kontrol	Mean		1,8546	,26327



	95% Confidence Interval for Mean	Lower Bound	1,1236	
		Upper Bound	2,5856	
	5% Trimmed Mean		1,8679	
	Median		2,1680	
	Variance		,347	
	Std. Deviation		,58869	
	Minimum		1,07	
	Maximum		2,40	
	Range		1,32	
	Interquartile Range		1,10	
	Skewness		-,672	,913
	Kurtosis		-2,346	2,000
Fluconazol	Mean		-2,1898	,56858
	95% Confidence Interval for Mean	Lower Bound	-3,7684	
		Upper Bound	-,6112	
	5% Trimmed Mean		-2,1843	
	Median		-1,4830	
	Variance		1,616	
	Std. Deviation		1,27138	
	Minimum		-3,60	
	Maximum		-,88	
	Range		2,72	
	Interquartile Range		2,38	
	Skewness		-,438	,913



		Kurtosis	-2,997	2,000	
Secang		Mean	-1,0310	,24029	
	95% Confidence Interval for Mean	Lower Bound	-1,6982		
		Upper Bound	-,3638		
		5% Trimmed Mean	-1,0493		
		Median	-1,0560		
		Variance	,289		
		Std. Deviation	,53731		
		Minimum	-1,52		
		Maximum	-,21		
		Range	1,31		
		Interquartile Range	,97		
		Skewness	,893	,913	
		Kurtosis	,303	2,000	
	delta_Soluble	Kelompok kontrol	Mean	46,5652	6,79739
95% Confidence Interval for Mean			Lower Bound	27,6926	
			Upper Bound	65,4378	
			5% Trimmed Mean	46,6856	
			Median	49,8140	
			Variance	231,023	
			Std. Deviation	15,19944	
			Minimum	28,16	
			Maximum	62,81	



	Range		34,65	
	Interquartile Range		29,78	
	Skewness		-,288	,913
	Kurtosis		-2,537	2,000
Fluconazol	Mean		-44,2912	8,86296
	95% Confidence Interval for Mean	Lower Bound	-68,8987	
		Upper Bound	-19,6837	
	5% Trimmed Mean		-44,5198	
	Median		-47,1060	
	Variance		392,760	
	Std. Deviation		19,81818	
	Minimum		-69,85	
	Maximum		-14,62	
	Range		55,23	
	Interquartile Range		31,40	
	Skewness		,501	,913
	Kurtosis		1,742	2,000
Secang	Mean		-20,4672	6,20522
	95% Confidence Interval for Mean	Lower Bound	-37,6956	
		Upper Bound	-3,2388	
	5% Trimmed Mean		-20,3349	
	Median		-23,8240	
	Variance		192,524	



Std. Deviation	13,87529	
Minimum	-37,36	
Maximum	-5,96	
Range	31,40	
Interquartile Range	26,80	
Skewness	,057	,913
Kurtosis	-2,315	2,000

## Kruskal-Wallis Test

Test Statistics<sup>a,b</sup>

	delta_IL6	delta_IL10	delta_Ekspresi	delta_Soluble	delta_koloni
Chi-Square	11,580	9,780	9,980	11,180	12,545
Df	2	2	2	2	2
Asymp. Sig.	,003	,008	,007	,004	,002

a. Kruskal Wallis Test

b. Grouping Variable: Kelompok





Optimization Software:  
[www.balesio.com](http://www.balesio.com)







Optimization Software:  
[www.balesio.com](http://www.balesio.com)